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Background: Diverse functions of microRNAs (miRNAs), including effects on tumorigenesis, proliferation, and
differentiation, have been reported, and several miRNAs have also been demonstrated to play an important role in
apoptosis. In this study, we investigated the possible role that miRNAs may play in the development of
chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor (EWS).
Methods: We screened doxorubicin (Dox)-resistant EWS cells to identify any distinct miRNA sequences that may
regulate the chemoresistance of EWS cells. The effects of miRNAs were evaluated using a chemosensitivity assay.
The possible target genes of the miRNAs were predicted using a web-based prediction program.
Results: We found miR-125b to be upregulated in two different Dox-resistant EWS cell lines. The upregulation of
miR-125b was also confirmed in the EWS tumors having survived chemotherapy regimen which includes
doxorubicin. When miR-125b was knocked down in EWS cells, both the Dox-resistant and parental cells showed an
enhanced sensitivity to doxorubicin, which was associated with the upregulation of the pro-apoptotic molecules,
p53 and Bak. Inversely, the overexpression of miR-125b in parental EWS cells resulted in enhanced drug resistance,
not only to doxorubicin, but also to etoposide and vincristine.
Conclusions: Our findings suggest that miR-125b may play a role in the development of chemoresistance in EWS
by suppressing the expression of the apoptotic mediators, such as p53 and Bak.
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The Ewing sarcoma/primitive neuroectodermal tumor
(EWS) is a malignant small round cell tumor of the
bone and soft tissues, and ranks second in frequency
among primary bone tumors in children and adoles-
cents. EWS is aggressive, and is associated with the
most unfavorable prognosis of all primary musculoskel-
etal tumors [1]. With the development of multimodal
therapeutic regimens that include chemotherapy, irradi-
ation, and surgery, long-term survival has been achieved
for approximately 70% of patients with localized disease
[2]. However, smaller improvements have been ob-
served for patients with recurrent disease, largely be-
cause their tumors are resistant to chemotherapy [3-6].* Correspondence: fukushi@med.kyushu-u.ac.jp
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reproduction in any medium, provided the orSeveral different mechanisms of chemoresistance in can-
cer have been elucidated. Enhanced drug-efflux pump ac-
tivity, changes in the intracellular metabolic machinery,
upregulation of DNA repair mechanisms, induction of
growth signaling, and impairment of apoptosis can all lead
to the acquisition of drug resistance [7]. In EWS, insulin-
like growth factor [8,9], c-kit [10,11], CD99 [12], CD133
[13], and p53 [14] have been reported to modulate the
anti-tumor effects of chemotherapy. We have previously
reported that P-glycoprotein (P-gp) and MRP1 were
overexpressed in doxorubicin (Dox)-resistant EWS cells,
and the cells treated with P-gp and MRP inhibitors showed
improved sensitivity to various drugs [15,16].
In addition to the above mechanisms, recent studies
have focused on the involvement of microRNA (miRNA)
during the acquisition of chemoresistance in cancer. The
miRNAs are small endogenous non-coding RNAs that
downregulate gene expression mainly by binding to the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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functions, including effects on tumorigenesis, prolifera-
tion, differentiation, and apoptosis have been reported
[18], and several miRNAs have been shown to have an
important role in the development of chemoresistance
[19]. Very recently, miR-34a was reported to regulate
the chemosensitivity of EWS cells and to be a prognostic
marker [20].
In the present study, we screened Dox-resistant EWS
cells for distinct miRNA sequences that may regulate
the chemosensitivity of EWS cells. Among 46 miRNAs,
miR-125b was commonly upregulated in two different
Dox-resistant cell lines. The upregulation of miR-125b
was also confirmed in the EWS tumors having survived
chemotherapy regimen which includes doxorubicin. We
demonstrate that miR-125b promotes multidrug resist-
ance by suppressing the expression of two apoptotic me-
diators, p53 and Bak. Further, our observations indicate
that the miR-125b-p53/Bak pathway plays a role during
the acquisition of Dox-resistance, and may potentially
serve as a therapeutic target for EWS.
Results
miR-125b enhances the chemoresistance of EWS cells to
doxorubicin
We examined the expression of miRNAs in Dox-resistant
EWS cells (VH-64/ADR) using the Luminex multiplex
assay system, and compared the results with those ob-
served in the parental VH-64 cells. Among the 46 different
miRNAs examined, miR-125b was the most highly
upregulated miRNA in the VH-64/ADR cells compared to
the parental cells (Figure 1A). The upregulation of miR-
125b in the resistant cells was then confirmed by quantita-
tive RT-PCR (the expression was 1.6-fold higher than that
of the parental cells) (Figure 1B). The upregulation of
miR-125b was also observed in another Dox-resistant
EWS cell line, WE-68/ADR (also 1.6-fold higher than the
parental WE-68 cells) (Figure 1B).
We were interested whether miR-125b was expressed in
human EWS tumors. We examined five EWS tumor sam-
ple pairs, consisting of samples collected before and after
chemotherapy using a VDC-IE (vincristine, doxorubicin,
cyclophosphamide, ifosfamide, and etoposide) or VAIA
(vincristine, actinomycin D, ifosfamide, and doxorubicin)
regimen. The expression levels of miR-125b were signifi-
cantly upregulated in the resection samples consisting of
viable tumor cells after chemotherapy (Figure 1C). The
common upregulation of miR-125b in two different Dox-
resistant cells, as well as in the clinical EWS tumor cells
having survived chemotherapy, suggests that miR-125b
may be involved in the acquisition of Dox-resistance in
EWS cells.
We next examined whether miR-125b could modulate
the chemosensitivity to doxorubicin in EWS cells. WhenmiR-125b was knocked down in the Dox-resistant cell
lines, significantly enhanced cell death was observed
(Figure 2A). The IC50 value shifted from 2570 to 1480 ng/
ml in the VH-64/ADR cells, and from 188 to 96 ng/ml in
the WE-68/ADR cells. The increased sensitivity to doxo-
rubicin was also observed in parental cells after down-
regulating miR-125b (Figure 2B, from 21.8 ng/ml to
12.0 ng/ml in VH-64 cells, and from 13.6 to 7.0 ng/ml in
WE-68 cells). The enhanced sensitivity to doxorubicin in-
duced by downregulating miR-125b was also observed in
three other EWS cell lines, RD-ES, SK-ES, and TC-71
(Additional file 1: Figure S1). To demonstrate the effect
of miR-125b was not off-target, we also knocked down
miR-93 which was about 1.5 times upregulated in Dox-
resistance cells (Figure 1A). Down-regulating miR-93
induced no significant changes in the chemosensitivity to
doxorubicin in EWS cells (Figure 2B). In contrast, when
miR125b was overexpressed in the parental cells, sig-
nificantly less cell death was induced by doxorubicin
(Figure 2C). The IC50 values shifted from 21.8 to 26.7 ng/
ml in the VH-64 cells, and from 8.1 to 12.6 ng/ml in the
WE-68 cells. These results indicate that miR-125b en-
hances the chemoresistance of EWS cells to doxorubicin.
miR-125b downregulates the pro-apoptotic molecules,
p53 and Bak
We have previously reported that drug-efflux pump was
overexpressed in Dox-resistance cells and developed
chemoresisitance [16]. An immunoblot assay revealed no
changes in P-gp in the Dox-resistant cells after down-
regulating miR-125b (Figure 3A). Since miR-125b can
affect chemosensitivity in the parental cells (Figure 2B)
where efflux pumps were almost undetectable (Figure 3A)
[16], additional mechanisms are likely to be involved in
miR-125b-related chemosensitivity. In addition to drug
efflux pumps, the induction of apoptosis is one of the
most important mechanisms by which various anti-cancer
drugs, including doxorubicin, exert their therapeutic ef-
fects [21]. Therefore, we investigated whether miR-125b
can modulate apoptosis. When parental EWS cells were
treated with doxorubicin, cleavage of caspase 3 was in-
duced, indicating the induction of apoptotic cell death
(Figure 3B). The enhanced cleavage of caspase 3 was
quantitatively confirmed by ELISA (Figure 3C). When
miR-125b was stably downregulated, enhanced cleavage of
caspase 3, along with enhanced cell death (Figure 2B), was
induced upon doxorubicin treatment (Figures 3B, C). This
suggests that miR-125b may modulate chemoresistance by
regulating apoptosis.
To elucidate the mechanism underlying how miR-
125b regulates apoptosis, we sought the target gene(s) of
miR-125b by using the web-based prediction program,
TargetScan (http://www.targetscan.org/). Among the vari-
ous predicted target genes, we focused on p53 and Bak,
Figure 1 The miRNA expression levels in Dox-resistant EWS cells. A) The relative miRNA expression in Dox-resistant VH-64/ADR compared to
parental VH-64 cells. The 46 miRNAs are listed in descending order. B) qRT-PCR was performed to confirm the differences in the expression of
miR-125b in two different Dox-resistant cell lines. RNU6B was used as an internal control. The data represent the means of three separate
experiments. The results are the means ± SD. *, P < 0.05. C) qRT-PCR was performed to confirm the differences in the expression of miR-125b in
EWS tumors before and after treatment. A comparison was made between the EWS tumors before (open biopsy sample) and after (resection
sample) VDC-IE or VAIA chemotherapy. RNU6B was used as an internal control. The gene expression levels were normalized to the average miR-125b
expression level of the open biopsy samples. The results are given as the means (solid lines) ± SD (dashed lines). *, P < 0.05.
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addition, both p53 and Bak have been reported to be dir-
ect targets of miR-125b in other types of cancer [22-25].
An immunoblot assay revealed that the expression levels
of p53 and Bak were upregulated when miR-125b was sta-
bly knocked down in the parental EWS cells (Figure 3D),
indicating that miR-125b suppressed these apoptotic
mediators.
To validate the binding of miR-125b to the 3′UTR of
p53 and Bak, we performed a luciferase reporter assay.
Consistent with the findings of previous reports [22-25],
the ectopic expression of miR-125b suppressed theactivity of luciferase construct containing the 3′UTR of
p53 and Bak (Additional file 2: Figure S2). These obser-
vations indicate that miR-125b directly targets p53 and
Bak in EWS cells.
We then examined the roles of p53 and Bak in Dox-
induced cell death. The p53 protein has been reported to
sensitize EWS Rh1 cells to doxorubicin [14]. Bak is a rela-
tively novel pro-apoptotic gene of the Bcl-2 family, and is
known to mediate Dox-induced apoptosis in myeloma
and lymphoma cell lines [26]. When p53 was knocked-
down, both the VH-64 and WE-68 parental cells showed
significant resistance to Dox-treatment (Figure 4A). The
Figure 2 The effects of miR-125b on the Dox-induced cytotoxicity in EWS cells. An antisense (miR-125b and miR-93) or control construct
was introduced into the Dox-resistant cells A), and the parental cells B) using a lentivirus. The cells were cultured with puromycin for 2 weeks to
ensure a stable knockdown, and then were seeded at 2 × 103 cells/well in 96 well plates. Twelve hours later, the cells were treated with various
concentrations of doxorubicin for an additional 48 h. The cell viability was detected by the CellTiter-GloTM Luminescent Cell Viability Assay. The
data represent the means of three separate experiments. The results are the means ± SD. *, P < 0.05. C) Cells were seeded at 2 × 103 cell/well in
96 well plates 36 h after transfection with 100 nM control or has-miR-125b miRNA Precursor. The cells were treated with various concentrations
of doxorubicin for an additional 48 h. The cell viability was detected by the CellTiter-GloTM Luminescent Cell Viability Assay. The data represent
the means of three separate experiments. The results are the means ± SD. *, P < 0.05.
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cells, and from 9.4 to 16.7 ng/ml in the WE-68 cells. In
contrast, when Bak was knocked down in either VH-64 or
WE-68 cells, no significant changes were observed in the
Dox-related cytotoxicity (Figure 4B).
We were interested in determining whether miR-125b
could modulate the chemosensitivity in an EWS cell line
expressing a truncated p53 mutant, SK-N-MC [27].
When miR-125b was knocked down in the cell, sig-
nificantly enhanced cell death was observed upon
Dox-treatment (the IC50 value shifted from 11.0 to
8.4 ng/ml), and the expression level of Bak was signifi-
cantly enhanced (Figure 5A). When Bak was knockeddown in the SK-N-MC cell line, the cells showed significant
resistance to Dox-treatment (Figure 5B). In contrast, when
p53 and Bak were overexpressed, the cells showed signifi-
cant sensitivity to doxorubicin (Figure 5C). These results
suggest that miR-125b enhances chemoresistance by
downregulating the p53/Bak apoptotic pathway in EWS
cells.
miR-125b regulates multidrug resistance in EWS cells
We have previously reported that Dox-resistant EWS
cells expressed P-gp and MRP1, and showed cross-
resistance to histone deacetylase inhibitors [16]. Because
the VDC-IE protocol has been accepted as a standard
Figure 3 Suppression of the expression of p53 and Bak by miR-125b. A) miR-125b was stably knocked down in Dox-resistant EWS cells, and
the whole cell lysates were subjected to an immunoblot analysis using antibodies against P-gp and β-actin. B), C) miR-125b was stably knocked
down in EWS cells, and the cells were incubated with or without 100 ng/ml of doxorubicin for 24 h. The whole cell lysates were subjected to an
immunoblot analysis using antibodies against caspase 3, cleaved caspase 3, and β-actin (B). The active caspase 3 levels were quantitated by using
ELISA (C). D) miR-125b was stably knocked down in EWS cells, and the whole cell lysates were subjected to an immunoblot analysis using
antibodies against p53, Bak, and β-actin.
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whether miR-125b could modulate the sensitivity to the
above drugs. Among the 5 drugs in the standard regimen,
cyclophosphamide and ifosfamide were not investigated
because they are prodrugs, and cannot be evaluated inin vitro studies. Instead, we used mafosfamide, a pre-
activated cyclophosphamide analog, as a subsutitute for
cyclophosphamide. As shown in Figure 6, Dox-resistant
cells showed significant cross-resistance to vincristine
and etoposide. The downregulation of miR-125b in the
Figure 4 Changes in Dox-induced cytotoxicity after p53 and Bak knockdown in EWS cells. The VH-64 or WE-68 parental cell lines were
transfected with 20 nM of siRNA against p53 (A) or Bak (B). After 48 h incubation, the cells were collected, and qRT-PCR and an immunoblot
analysis were performed to confirm the effects of the siRNA. The cells were seeded at 2 × 103 cells/well in 96 well plates and treated with various
concentrations of doxorubicin for 48 h. The cell viability was determined by the CellTiter-GloTM Luminescent Cell Viability Assay. The data
represent the means of three separate experiments. The results are the means ± SD. *, P < 0.05.
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and etoposide (Figure 6A, C). In contrast, when miR-
125b was overexpressed in the parental cells, reduced
cytotoxicity was observed upon treatment with vincris-
tine and etoposide (Figure 6B, C). Intriguingly, the Dox-
resistant cells showed almost the same sensitivity tomafosfamide as the parental cells. Knocking down miR-
125b enhanced the sensitivity of both parental and resist-
ant cells to mafosfamide (Additional file 3: Figure S3).
These observations suggest that miR-125b enhances the
chemoresistance to multiple drugs used in the standard
regimen for treating EWS.
Figure 5 Changes in Dox-induced cytotoxicity after the downregulation of miR-125b and Bak in p53-truncated EWS cells. A) miR-125b
was stably knocked down in SK-N-MC cells which express a truncated mutant of p53. The cells were seeded at 2 × 103 cells/well in 96 well plates
and cultured for 12 h, then were treated with various concentrations of doxorubicin for an additional 48 h. (Left) The cell viability was determined
by the CellTiter-GloTM Luminescent Cell Viability Assay. The data represent the means of three separate experiments. The results are the means ± SD. *,
P < 0.05. (Right) The whole cell lysates were subjected to an immunoblot analysis using antibodies against Bak and β-actin. B) SK-N-MC cells were
transfected with 20 nM of siRNA against Bak. (Upper) After 48 h incubation, the cells were collected, and qRT-PCR and an immunoblot analysis were
performed to confirm the effect of the siRNA. (Lower) Cells were seeded at 2 × 103 cells/well in 96 well plates, and were treated with various
concentrations of doxorubicin for 48 h. The cell viability was determined by the CellTiter-GloTM Luminescent Cell Viability Assay. The data represent
the means of three separate experiments. The results are the means ± SD. *, P < 0.05. C) p53, Bak or mock construct was introduced into SK-N-MC cells
using a lentivirus. After 96 h incubation, the cells were seeded at 2 × 103 cells/well in 96 well plates. Twelve hours later, the cells were treated with
various concentrations of doxorubicin for an additional 48 h. The cell viability was detected by the CellTiter-GloTM Luminescent Cell Viability Assay. The
data represent the means of three separate experiments. The results are the means ± SD. *, P < 0.05. Immunoblot analyses were performed to confirm
the effects of the lentivirus induction.
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One major mechanism of drug resistance in cancer
cells is the evasion of apoptosis [7,29]. Recent findings
have revealed that miRNAs can modulate drug resist-
ance by impairing the apoptotic pathway in various
cancers [19,24,30,31]. In this study, we observed the
upregulation of miR-125b in Dox-resistant EWS cells.
When miR-125b was knocked down in EWS cells, both
the Dox-resistant cells and the Dox-sensitive parentalcells showed enhanced chemosensitivity to doxorubi-
cin, and this was associated with the upregulation of
the pro-apoptotic molecules, p53 and Bak. Conversely,
overexpressing miR-125b in EWS cells resulted in en-
hanced drug resistance. We have previously reported the
involvement of ABC transporters during the acquisition of
multidrug resistance in EWS cells [15,16]. However, the
drug resistance in those cells was not fully reversed in the
presence of efflux pump inhibitors, so it was concluded
Figure 6 (See legend on next page.)
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Figure 6 The effects of miR-125b on the resistance of EWS cells to etoposide and vincristine. A) miR-125b was stably knocked down in
Dox-resistant EWS cells. The cells were seeded at 2 × 103 cells/well in 96 well plates, cultured for 12 h, and then treated with various
concentrations of vincristine or etoposide for an additional 48 h. The cell viability was determined by the CellTiter-GloTM Luminescent Cell
Viability Assay The data represent the means of three separate experiments. The results are the means ± SD. *, P < 0.05. B) Cells were seeded at
2 × 103 cells/well in 96 well plates 36 h after transfection with 100 nM control or has-miR-125b miRNA Precursor. The cells were treated with
various concentrations of vincristine or etoposide for an additional 48 h. The cell viability was determined by the CellTiter-GloTM Luminescent
Cell Viability Assay. The data represent the means of three separate experiments. The results are the means ± SD. *, P < 0.05. C) The drug
sensitivity of the EWS clones to various anticancer agents. IC50 showed drug concentrations that inhibited cell survival by 50%.
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to be involved. Our present observations clearly revealed
the involvement of miR-125b during the acquisition of
multidrug resistance in EWS cells.
It is known that miR-125b is a vertebrate homologue
of the C. elegans microRNA lin-4, which regulates the
reiterations of stem cells in C. elegans [32]. Similar to
lin-4, miR-125b has been shown to regulate the homeo-
stasis of mammalian neural and hematopoietic stem cells
[33,34]. Several targets of miR-125b have been identified,
including ETS [35], ERBB [36], p53 [37], Bak [23,24],
and Lin28 [34], thus suggesting the involvement of miR-
125b and its targets in proliferation and apoptosis.
Recent reports suggest that miR-125b functions as a
tumor suppressor in some types of tumors, such as breast
cancer [35,38], thyroid cancer [39], and hepatocellular car-
cinoma [40]. In contrast, miR-125b was shown to function
as an oncogene in B-cell leukemia [41], endometrial carcin-
oma [42], and colorectal cancer [43]. Shi et al. reported that
the downregulation of miR-125b induced growth inhibition
of prostate cancer cells, whereas the overexpression of
miR-125b enhanced cell growth [23]. Our findings revealed
that miR-125b acts as an oncogene in EWS cells by
targeting p53 and Bak.
The tumor suppressor p53, recognized as the “guardian
of the genome”, regulates many downstream genes and
plays a pivotal role in regulating the cell cycle and cell
death. Recent studies have revealed that several miRNAs,
including miR-125b, directly target p53 [22]. The loss of
miR-125b increases widespread p53-dependent apoptosis,
leading to severe defects in zebrafish embryos [37]. Direct
suppression of p53 by miR-125b affects the camptothecin-
induced apoptosis in various cancer cell types [25], and
was assumed to be associated with a poor prognosis of
colorectal cancer [43]. The results of our current study are
consistent with these previous reports that miR-125b acts
as an oncogene by suppressing p53-dependent apoptosis
(Figure 3). Intriguingly, an anti-apoptotic role of miR-125b,
mediated through the suppression of multiple pro-
apoptotic regulators in the p53 network, is conserved in
vertebrates [37], suggesting the importance of miR-125b in
regulating p53.
Although the function of p53 is reported to be dis-
rupted in a wide variety of tumors, p53 mutations areuncommon in EWS. The majority of EWS tumors ex-
press wild-type p53 [44]. Instead of genetic alterations,
the inactivation of p53 during the development and pro-
gression of EWS has been explained by the interaction
between p53 and the EWS/FLI1 fusion gene [45]. We
have reported that EWS/FLl1 interacts with p53, impairs
its transcriptional activity, and inhibits the expression of
its downstream target genes [46]. In addition to these
post-translational modifications by EWS/FLI1, miR-125b
may regulate the expression of p53 post-transcriptionally
by interacting with its 3′UTR in EWS [22,37].
Bak is a pro-apoptotic mitochondrial membrane protein,
usually inactivated by the formation of complexes with the
anti-apoptotic Bcl2 family protein, Mcl1. Bak has been
reported to be a target of miR-125b, which has been impli-
cated in the androgen-independent growth of prostate can-
cer cells [23], and also in paclitaxel-induced apoptosis in
breast cancer cells [47]. In this study, we showed that Bak
is also involved in miR-125b-mediated Dox-resistance
in EWS cells. The downregulation of Bak reduced che-
mosensitivity only in the p53-truncated SK-N-MC cells
(Figure 5B), indicating the importance of wild-type p53
during Dox-induced cytotoxicity in EWS. Of note, p53
was shown to bind to Bak following genotoxic stress, and
to induce its oligomerization, leading to cytochrome c re-
lease [48]. Although we have not examined the direct
interaction of p53 with Bak in EWS cells, these observa-
tions indicate that, in the absence of p53, the miR-125b-
Bak axis plays a role in the chemosensitivity in EWS cells.
The role of microRNAs in EWS remains largely un-
clear. Very recently, Italian investigators revealed the in-
volvement of miR-34a in the chemoresistance of EWS
[20]. They screened miRNAs by discriminating EWS pa-
tients with different clinical outcomes and successfully
identified miR-34a as a regulator of chemosensitivity and
a possible prognostic marker. On the other hand, we
screened Dox-resistant EWS cells and found miR-125b
to be upregulated in the resistant cells. Upregulation of
miR-125b was also confirmed in the EWS tumors having
survived chemotherapy regimens that included doxo-
rubicin. Although the screening methods are different in
these studies, both studies clearly demonstrate the in-
volvement of miRNAs in the development of chemo-
resistance in EWS.
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tumors, including B-cell leukemia, endometrial carcinoma
and colorectal cancer [41-43]. In regard to Dox-resistant
cell lines, upregulation of miR-125b was observed in the
malignant peripheral nerve sheath tumor cells, FU-
SFT9817, but not in the osteosarcoma cell line MNNG
(Additional file 4: Figure S4). It appears that the upregu-
lation of miR-125b in tumor cells occurs in a cell type-
dependent manner. Thus far, the underlying mechanism
responsible for this upregulation remains unclear. The
contribution of NF-kB p65 binding sites as well as CpG-
rich regions upstream of miR-125b-1 in the regulation
of miR-125b has been postulated [35,47]. We observed
no differences in the copy numbers of miR-125b genes
between the parental and Dox-resistant EWS cells
(Additional file 5: Figure S5), suggesting epigenetic
regulation of the miR-125b expression in Dox-resistant
EWS cells. Further studies are required to elucidate the
mechanisms regulating the miR-125b expression.
Since the introduction of the VDC-IE regimen, the
5-year survival rates for patients with localized disease
have ranged from 60 to 70% [1,28]. Nevertheless, EWS still
has a low survival rate because of the frequent develop-
ment of recurrence and/or metastatic lesions, which are
usually associated with the acquisition of multidrug resist-
ance [28]. We have observed that miR-125b significantly
affected the chemosensitivity of EWS to doxorubicin, vin-
cristine, etoposide (Figure 6), and mafosfamide (Additional
file 3: Figure S3). As shown in Figure 1C, miR-125b was
significantly upregulated in EWS tumors after VDC-IE or
VAIA treatment. Upregulation of miR-125b upon chemo-
therapy have been reported in colorectal cancer [49], and
breast cancer [47]. These observations suggest that the ac-
quisition of drug resistance may be regulated, at least
partly, via the miR-125b-p53/Bak pathway.Conclusions
In summary, miR-125b was commonly upregulated in
Dox-resistant EWS cells as well as in EWS tumors having
survived chemotherapy. miR-125b led to the development
of chemoresistance by suppressing the expression of p53
and Bak, and repression of miR-125b sensitized EWS cells
to apoptosis induced by treatment with various cytotoxic
drugs. Elucidating the involvement of miRNAs in the de-
velopment of chemoresistance should be required to fur-
ther improve the clinical prognosis for EWS.Methods
Reagents
Doxorubicin was obtained from Kyowa Hakko (Tokyo,
Japan). Etoposide was obtained from Calbiochem (San
Diego, CA). Vincristine and mafosfamide were obtained
from Wako (Osaka, Japan).Cells and cell culture
The human EWS cell lines, VH-64 and WE-68 (with wild
type p53), and SK-N-MC (with a p53 truncation), and
RD-ES, SK-ES, and TC-71 (with mutant type p53) were
cultured in RPMI-1640 (Invitrogen, Carlsbad, CA) con-
taining 10% fetal bovine serum (HyClone Laboratories, Inc.,
Logan, UT). The Dox-resistant EWS clones VH-64/ADR
and WE-68/ADR were established and characterized in our
laboratory [16], and cultured in RPMI-1640 containing 10%
fetal bovine serum with 100 ng/ml of doxorubicin. The cells
were incubated at 37°C in a humidified atmosphere
containing 5% CO2.
miRNA extraction from clinical samples
The study population consisted of 11 serial cases re-
trieved from the archives of the Department of Ana-
tomic Pathology, Pathological Sciences, Graduate School
of Medical Science, Kyushu University, Japan. The tissue
specimens were collected during primary tumor open bi-
opsy at diagnosis between 2002 and 2008. In each case,
a diagnosis of EWS was made based on the histological
features of the specimen. From these 11 cases, six cases
were excluded because of a lack of availability of ad-
equate tissue. The remaining five cases were treated with
systemic VDC-IE or VAIA regimen [1], and then the tu-
mors were resected.
The expression profiles of miRNAs were reported to
be in good correlation between fresh frozen and formalin-
fixed, paraffin-embedded (FFPE) samples [50,51]. Therefore,
all samples were prepared as FFPE sections. Thereafter,
4 μm sections of FFPE tissues were deparaffinized with xy-
lene, washed in ethanol, and digested with proteinase K.
Total RNA was extracted using a miRNeasy FFPE kit
(Qiagen, Valencia, CA). Ten nanograms of total RNA
from each sample were used for cDNA synthesis. The In-
stitutional Review Board at Kyushu University approved
the use of human specimens for this study (Reference
number 21-124).
Quantitative real-time PCR (qRT-PCR)
For the miRNA expression analysis, total RNA was
purified from harvested cells using a miRNeasy Mini Kit
(Qiagen). The total RNA was used in a reverse tran-
scription reaction with a MiScript Reverse Transcrip-
tion Kit (Qiagen). Real-time PCR was carried out using
a LightCycler 1.5 (Roche Diagnotics, Indianapolis, IN)
with miRNA-specific primers (Qiagen) according to the
manufacturer’s instructions (miScript SYBR Green PCR
kit, Qiagen). RNU6B was used as an internal control.
The RT reactions were performed using the following
conditions: an initial denaturation step at 95°C for
15 min, followed by 40 cycles of denaturation at 94°C
for 15 s, annealing at 55°C for 30 s, and extension at
70°C for 30 s.
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was extracted using an RNeasy kit (Qiagen). The total
RNA was used in a reverse transcription reaction with
SuperScriptII reverse transcriptase (Invitrogen). Real-
time PCR was carried out using a LightCycler 1.5 with
mRNA-specific primers according to the manufacturer’s
instructions (Perfect Real Time, Takara Bio, Shiga, Japan).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was used as an internal control. The RT reactions were
performed under the following conditions: an initial de-
naturation step at 95°C for 5 s, followed by 40 cycles of
denaturation at 95°C for 10 s, and annealing at 60°C for
30 s. The following primers were used: Bak (forward:
5′-CTTCGTGGTCGACTTCATGCT-3′ and reverse: 5′-
GGACCATTGCCCAAGTTCAG-3′; product size 93 bp),
p53 (forward: 5′-ACTAAGCGAGCACTGCCCAAC-3′
and reverse: 5′-CCTCATTCAGCTCTCGGAACATC-3′;
product size 130 bp), and GAPDH (forward: 5′-GAAGGT
GAAGGTCGGAGTC-3′ and reverse: 5′-GAAGATGGT
GATGGGATTTC-3′; product size 226 bp).
The expression levels of miRNAs, mRNAs, and DNAs
were calculated using the LightCycler version 3.5 software
program (Roche Diagnotics). A negative control was also
prepared using distilled water instead of a DNA template.
The assay was performed in triplicate and was repeated in
at least three separate experiments.
siRNA and miRNA experiments
The cells were seeded at 1.5 × 105 cells per well in 6 well
plates. After 24 h in culture, the cells were transfected
with p53 siRNA (Ambion ID 605), Bak siRNA (Ambion
ID 1880), has-miR-125b miRNA Precursor (Ambion
ID PM10148) or Silencer Negative Control #1 siRNA
(Ambion, Austin, TX) using Lipofectamine2000 (In-
vitrogen) according to the manufacturer’s protocols.
The introduction of the miRNAs was confirmed by
qRT-PCR (Additional file 6: Figure S6), and the in-
troduction of the siRNAs was confirmed by qRT-PCR
and immunoblotting. Thirty-six hours after transfec-
tion, a chemosensitivity assay was performed as de-
scribed below.
Chemosensitivity assay
For the chemosensitivity assay, cells were seeded at 2 × 103
cells per well in 96 well plates. After 12 h incubation, vari-
ous concentrations of drugs were added to the medium.
After another incubation for 48 h, the number of viable
cells in each well was measured using the CellTiter-
GloTM Luminescent Cell Viability kit (Promega, Madison,
WI), according to the manufacturer’s protocol. Before the
use of Dox-resistant clones in this assay, they were cul-
tured in medium without doxorubicin for 10 days. The
chemosensitivity assay was carried out in triplicate and was
repeated at least three times in separate experiments.Profiling microRNA expression by Luminex
The total RNA from VH-64 and VH-64/ADR cells was
extracted using a Vantage™ Total RNA Purification Kit
(Origene, Rockville, MD). A 2 μg aliquot of total RNA was
labeled with biotin by the Vantage™ microRNA Labeling
Kit (Origene) as described in the manufacturer’s proto-
col. The labeled total RNA was hybridized to Bead Mix
(Vantage™ microRNA Multiplex Detection Kit Oncology
Detection Panel, Origene) at 60°C by using a thermocycler
for one hour. The hybridized reactions were transferred to
96 well filter plates. After several washing steps, the filter
plate was read using a Luminex100 instrument (Luminex
Corp., Austin, TX) [53].
Lentiviral vector construction and production
miRNA expression vectors (miRZip Anti-miR-125b
microRNA Construct, miRZip Anti-miR-93 microRNA
Construct and Scramble Hairpin Control Anti-microRNA
Construct, System Biosciences, Mountain View, CA) and
the Lentivirus Package plasmid mix (System Biosciences)
were co-transfected into 293TN (System Biosciences) cells
with Lipofectamine2000 (Invitrogen) according to the
manufacturer’s protocol. The culture supernatants were
collected 48 h post-transfection. The supernatant was con-
centrated by PEG-it Virus Precipitation Solution (System
Biosciences), and the concentrated supernatant was used
to infect target cells.
To create p53 and Bak lentiviral vectors, we inserted
p53 and Bak cDNA into pCDH-EF1-MCS-IRES-Puro
(System Biosciences). These vectors were co-transfected
with Package plasmid mix into 293TN, and the concen-
trated supernatant was used.
Lentiviral infection
Cells were plated at a density of 0.5 × 105 cells per well
in 24 well plates with RPMI (with serum, but without
antibodies). After 24 h incubation, the cells were trans-
fected with lentivirus particles using the TransDux Virus
Transduction Reagent (System Biosciences). Two days
after transfection, puromycin was added to the me-
dium to establish cells with stable miR-125b knock
down. Almost all cells were confirmed to be infected
by counting GFP-positive cells 2 weeks after the trans-
fection (Additional file 7: Figure S7).
Western blot analysis
The cells were washed twice with ice-cold PBS, scraped,
collected in a microcentrifuge tube, and then centrifuged.
The cells were lysed using CelLytic (Sigma Aldrich, St.
Louis, MO) with a protease inhibitor cocktail (Complete
Mini, EDTA-free; Roche Diagnotics). After incubating the
cells for 10 min on ice, the cellular debris was pelleted by
centrifuging for 15 min at 12000 × g at 4°C. The protein
quantity in the lysate was determined using a Bradford
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were boiled for 5 min, and each of the samples was sep-
arated on a 4–12% gradient pre-cast MOPS polyacryl-
amide gel (Novex, San Diego, CA) and transferred onto
a nitrocellulose membrane. The filter was blocked with
TBS containing 5% non-fat dry milk and 0.1% Tween20
for 1 h at room temperature. The filter was then incu-
bated overnight with the appropriate primary antibodies
at 4°C. The following primary antibodies were used: P-gp
(Alexis Biochemicals, San Diego, CA), p53 and β-actin
(Santa Cruz Biotechnology, Santa Cruz, CA), Bak (Abcam,
Cambridge, UK), caspase 3 (BD Biosciences, San Jose,
CA), and cleaved caspase 3 (Cell Signaling, Beverly,
MA). After washing the filter, a horseradish peroxidase-
conjugated secondary antibody (Santa Cruz Biotechnology)
was added, and the filter was incubated at room tem-
perature for 1 h. After a final wash with TBST, the immu-
noreactivity of the blots was detected using an enhanced
chemiluminescence (ECL) detection system (Amersham,
Buckinghamshire, UK).
Active caspase 3 ELISA
Cells were seeded at 5 × 105 cells per well in 12 well plates
and incubated with 100 ng/ml doxorubicin. After 24 h
incubation, the cells were harvested. The concentrations
of active caspase 3 were measured according to the manu-
factures instructions (R&D Systems, Minneapolis, MN).
Statistical analysis
Statistical comparisons were performed using Student’s
t-test. The minimal level of significance was considered
to be P = 0.05.
Consent
Written informed consent was obtained from the patient
for publication of this report and any accompanying
images.
Additional files
Additional file 1: Figure S1. The effects of miR-125b on the Dox-
induced cytotoxicity in EWS cells. miR-125b was stably knocked down in
EWS cells (RD-ES, SK-ES, and TC-71). The cells were seeded at 2 × 103
cells/well in 96 well plates, cultured for 12 h, and then treated with
various concentrations of doxorubicin for an additional 48 h. The cell
viability was determined by the CellTiter-GloTM Luminescent Cell Viability
Assay The data represent the means of three separate experiments. The
results are the means ± SD. *, P < 0.05.
Additional file 2: Figure S2. 3’UTR-luciferase assay for p53 and Bak.
Reporter luciferase vectors containing the 3’UTR of p53 and Bak were
purchased from Ambion, and random control vectors were purchased
from Switchgear genomics (Menlo Park, CA). Cells were seeded at a
density of 2 × 105 cells per well in 12 well plates. The cells were co-
transfected with luciferase reporters and has-miR-125b miRNA Precursor
or Silencer Negative Control #1 siRNA. After 36 h incubation, the cells
were collected. The luciferase activity was measured using a dual
luciferase reporter assay (Promega). The pRL-TK vector was used as aninternal control. The results are expressed as the relative luciferase activity
(firefly Luc/Renilla Luc). The results are the means ± SD. *, P < 0.05.
Additional file 3: Figure S3. The effects of miR-125b on the sensitivity
of EWS cells to mafosfamide. An antisense or control construct was
introduced into the parental cells (A), and the Dox-resistant cells (B) using
a lentivirus. The cells were cultured with puromycin for 2 weeks to
ensure a stable knockdown, and then were seeded at 2 × 103 cells/well in
96 well plates. Twelve hours later, the cells were treated with various
concentrations of mafosfamide for an additional 48 h. The cell viability
was detected by the CellTiter-GloTM Luminescent Cell Viability Assay. The
data represent the means of three separate experiments. The results are
the means ± SD. *, P < 0.05.
Additional file 4: Figure S4. The miRNA expression levels in the Dox-
resistant tumor cells. qRT-PCR was performed to investigate the
expression of miR-125b in Dox-resistant cell lines. RNU6B was used as an
internal control. The data represent the means of three separate
experiments. The results are the means ± SD. *, P < 0.05.
Additional file 5: Figure S5. The copy number analysis of miR-125b in
VH-64 and VH-64/ADR. Quantitative-PCR was performed to examine the
copy numbers of miR-125b in VH-64 and VH-64/ADR. DNA was extracted
using DNeasy (Qiagen), and real-time PCR was carried out using a
LightCycler 1.5 with specific primers according to the manufacturer’s
instructions (Perfect Real Time, Takara Bio). The GAPDH and TNSALP
(Tissue non-specific alkaline phosphatase) genes were used as control 1
and control 2, respectively. The PCR reactions were performed under the
following conditions: an initial denaturation step at 95°C for 5 s, followed
by 40 cycles of denaturation at 95°C for 10 s and annealing at 60°C for
30 s. The following primers were used: miR-125b-1 (forward: 5’- CTGGT
CACCTGATCCCATCT-;3’ and reverse: 5’-ATTGTTGCGCTCCTCTCAGT-3’;
product size 217 bp), miR-125b-2 (forward: 5’-CCGCATCAAACCAGACT
TTT-3’ and reverse: 5’-GGATGGGTCATGGTGAAAAC-3’; product size
228 bp), control 1 (forward: 5’-CAACGAATTTGGCTACAGCA-3’ and reverse:
5’- AGGGGTCTACATGGCAACTG-3’; product size 195 bp), and control 2
(forward: 5’- AGGAGCACGAGAGACTGAGG-3’ and reverse: 5’- CTGGCT
GCTGTCATGTTCAG-3’; product size 232 bp). The data represent the
means of three separate experiments.
Additional file 6: Figure S6. The induction of miR-125b in parental
EWS cells. The VH-64 or WE-68 parental cell lines were transfected
with100 nM control or has-miR-125b miRNA Precursor. After 48 h
incubation, the cells were collected, and qRT-PCR was performed to
confirm the expression of miR-125b.
Additional file 7: Figure S7. The knockdown of miR-125b using the
lentivirus. Cells were infected with the miRZip lentivirus construct, then
the induction of the anti-miR-125b was confirmed by GFP-positivity in
almost all of the cells.
Abbreviations
miRNA: microRNA; EWS: Ewing sarcoma/primitive neuroectodermal tumor;
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